NCI-H1568 Xenograft Rat Model Service for Lung (Non-Small Cell) Cancer

The NCI-H1568 xenograft rat model captures the intratumoral heterogeneity and EGFR-TKI resistance landscape of lung adenocarcinoma within a physiologically intact host amenable to longitudinal pharmacodynamic interrogation. Alfa Cytology architects and validates these rat xenograft systems with granular attention to stem cell population dynamics, tumor microenvironment fidelity, and reproducible endpoint readouts—equipping your preclinical lung cancer program with actionable data from early pharmacological profiling through late-stage combination therapy assessment.

Overview of NCI-H1568 Xenograft Rat Model for Lung (Non-Small Cell) Cancer

NCI-H1568 is a human lung adenocarcinoma cell line originally established in 1986 from a lymph node metastasis of a 48-year-old female patient. Genetically, this line harbors wild-type EGFR and exhibits pronounced intratumoral heterogeneity, comprising a hierarchical spectrum of cell populations ranging from quiescent lung cancer stem cells (LuCSCs) to highly proliferative differentiated progeny. This cellular polymorphism renders NCI-H1568 particularly valuable for modeling therapy-resistant tumor subpopulations and evaluating agents targeting cancer stemness. When propagated as a xenograft in immunodeficient rats, NCI-H1568 tumors retain their heterogeneous architecture, with LuCSC-driven holoclones generating acini-like structures and differentiated progeny forming dense spheroids—morphologies that closely mirror the histopathological complexity of human NSCLC. The rat host's larger blood volume and anatomical scale further enable serial pharmacokinetic sampling, high-resolution imaging, and repeated tumor biopsies without compromising animal welfare.

Fig 1. Flowchart describing how the sensitive and resistant PDX models were selected from a set of available PDX models. (Tavassoly, Iman, et al., 2019)

In the preclinical arena, NCI-H1568 rat xenografts serve as a critical model for interrogating resistance mechanisms to EGFR tyrosine kinase inhibitors, given the line's documented insensitivity to Erlotinib, Lapatinib, and Afatinib at clinically relevant concentrations. The model is equally suited for evaluating anti-stemness therapeutics—such as Salinomycin and Metformin—which selectively target the LuCSC compartment while sparing differentiated bulk tumor cells. Orthotopic implantation into the rat lung parenchyma or bronchial tree preserves the native alveolar architecture and vascular supply, enabling studies of local invasion, intravasation, and distant metastasis. Subcutaneous engraftment, meanwhile, provides rapid tumor accessibility for primary drug screening and biomarker modulation studies. Collectively, the NCI-H1568 rat xenograft platform bridges the gap between in vitro cell culture and human disease, offering a robust substrate for advancing NSCLC therapeutics through the preclinical pipeline.

Cell Line Information: NCI-H1568

NCI-H1568 is among the most phenotypically heterogeneous NSCLC cell lines available, harboring distinct clonal subpopulations with divergent proliferative, invasive, and drug-sensitivity profiles. The table below synthesizes its essential biological and molecular attributes relevant to xenograft construction and therapeutic screening.

Our Services

Alfa Cytology brings deep expertise in NCI-H1568 xenograft rat model development, offering a full-spectrum service portfolio that spans cell line authentication, immunodeficient rat procurement, surgical implantation, and multi-modal endpoint characterization. Our scientists understand the nuances of modeling intratumoral heterogeneity and therapy-resistant subpopulations—capabilities that translate directly into more predictive preclinical data for your NSCLC therapeutic program. Whether you need a rapid subcutaneous screen to benchmark EGFR-TKI resistance or a sophisticated orthotopic lung model to evaluate anti-stemness agents, we architect each study with the precision and rigor your pipeline demands.

Workflow of NCI-H1568 Xenograft Rat Model Construction

Building a reproducible NCI-H1568 xenograft rat model hinges on meticulous cell culture stewardship, precise surgical execution, and standardized in-life monitoring. The workflow below maps each phase from cell preparation through terminal analysis, ensuring consistent tumor engraftment and biologically meaningful readouts.

1. Cell Culture Maintenance and Pre-Inoculation Validation: NCI-H1568 cells are propagated in RPMI-1640 medium with 10% FBS at 37°C under 5% CO₂. Prior to in vivo deployment, cells undergo STR authentication, mycoplasma PCR screening, and passage-number verification (typically restricted to <P20) to safeguard genetic fidelity and tumorigenic potential. Cell heterogeneity is monitored via colony morphology assessment to ensure representative LuCSC and differentiated progeny ratios.
2. Immunodeficient Rat Acclimatization and Cohort Assembly: Athymic nude (RNU) or severely immunocompromised rat strains are quarantined for a minimum of five days upon arrival. Baseline body weights, clinical observations, and hematology panels are recorded. Animals are randomized into experimental cohorts using body-mass stratification to minimize baseline variability.
3. Cell Harvest, Enumeration, and Formulation: At 70–80% confluence, cells are detached with 0.05% trypsin-EDTA, washed in sterile PBS, and counted via automated hemocytometer. Viability is confirmed to exceed 95% by trypan blue exclusion. Cells are resuspended at 1–5 × 10⁶ cells/mL in ice-cold PBS or serum-free medium. For enhanced engraftment, the suspension may be mixed 1:1 with Matrigel.
4. Tumor Cell Implantation: For subcutaneous models, 100–200 µL of cell suspension (1–5 × 10⁶ viable cells) is injected into the subcutaneous flank using a 25-gauge needle. For orthotopic lung models, a lateral thoracotomy or ultrasound-guided percutaneous approach is employed to deliver 2–5 × 10⁶ cells directly into the rat lung parenchyma. The incision is closed with absorbable sutures, and post-operative analgesia is administered per institutional guidelines.
5. Post-Implantation Surveillance and Tumor Tracking: Animals are housed in individually ventilated cages under SPF conditions with daily health checks. Tumor dimensions are measured two to three times weekly using digital calipers, with volumes computed as: Volume = (length × width²) × 0.5. Body weights and clinical scores are documented at each measurement interval to detect early signs of toxicity or morbidity.
6. Therapeutic Intervention and Serial Sampling: Upon tumors reaching the protocol-specified volume (typically 100–200 mm³), animals are randomized into vehicle and treatment arms. Test articles are delivered via oral gavage, intravenous injection, intraperitoneal administration, or intratumoral injection as specified by the study protocol. Serial blood collections (up to 300 µL per draw) enable pharmacokinetic profiling and circulating biomarker analysis without compromising animal welfare.
7. Terminal Necropsy and Multi-Modal Tissue Analysis: At study conclusion, animals are humanely euthanized per IACUC-approved protocols. Primary tumors are excised, weighed, photographed, and subdivided for formalin fixation, snap-freezing, and live-cell dissociation. Distant organs—lung, liver, lymph nodes, brain—are inspected for metastatic foci via H&E staining, IHC (Ki-67, CD31, cleaved caspase-3, Nanog), and quantitative PCR. Circulating tumor DNA and cytokine panels are analyzed from terminal blood draws to construct integrated pharmacodynamic profiles.

Fig 2. NCI-H1568 Xenograft Rat Model construction workflow.

Case Study-NCI-H1568 Xenograft Rat Model Development

In a representative preclinical program, female athymic nude rats received subcutaneous flank implantation of NCI-H1568 cells, achieving a 100% tumor take rate with palpable masses emerging within 10–12 days. Tumors exhibited heterogeneous histology comprising compact epithelial holoclone regions consistent with LuCSC nests, adjacent to more loosely organized mesenchymal-appearing areas characteristic of 1st DF progeny, and dense spheroid zones resembling 2nd DF differentiation. A parallel cohort was challenged with an EGFR-TKI at doses approximating human equivalent exposure, showing minimal tumor growth inhibition and confirming the line's documented resistance profile. Conversely, a combination arm incorporating an anti-stemness agent with a cytotoxic backbone produced measurable reduction in tumor volume alongside decreased Nanog⁺ cell frequency within residual tumor tissue, as quantified by flow cytometry and immunohistochemistry. These findings underscore the NCI-H1568 rat xenograft platform as a predictive model for dissecting therapy-resistant subpopulations and benchmarking next-generation NSCLC therapeutics.

Why Choose Alfa Cytology?

When your NSCLC program demands a xenograft partner that understands the complexity of intratumoral heterogeneity and therapy resistance, Alfa Cytology delivers unmatched scientific depth and operational reliability. Our NCI-H1568 rat model services are built on validated biology, surgical precision, and analytical breadth—translating into data you can stake critical decisions on.

• Heterogeneity-Aware Model Validation — We monitor and report LuCSC-to-differentiated cell ratios within each NCI-H1568 batch, ensuring your study captures the full spectrum of tumor biology rather than a simplified monoclonal snapshot.
• Specialized Surgical Expertise — Our veterinary surgeons perform both subcutaneous and orthotopic lung implantations with high fidelity, including ultrasound-guided percutaneous delivery that minimizes surgical trauma and accelerates recovery.
• Integrated Resistance Profiling — In-house capabilities for EGFR-TKI resistance confirmation, stem cell marker quantification (Nanog, CD133, ABCG2), and EMT marker analysis (vimentin, N-cadherin, Zeb1) provide mechanistic depth beyond simple tumor volume metrics.
• Adaptive Study Designs — We accommodate complex protocols including multi-arm combination studies, sequential dosing schedules, cross-resistance matrices, and interim biomarker-driven adaptive randomization.
• Regulatory-Ready Documentation — Every protocol is IACUC-reviewed, every data point is audit-trailed, and every final report is structured to support IND submissions, investor due diligence, and peer-reviewed publication.
• Dedicated Scientific Stewardship — A PhD-level project scientist is assigned to each engagement, providing weekly data summaries, real-time troubleshooting, and strategic input to ensure your study evolves in lockstep with your development priorities.

Contact Us

Ready to interrogate EGFR-TKI resistance and cancer stemness in a validated NCI-H1568 xenograft rat model? Reach out to us today to discuss your study design, compound characteristics, and analytical requirements. Our preclinical oncology specialists will collaborate with you to build a customized experimental framework that yields robust, decision-grade data and propels your NSCLC therapeutic candidate toward its next development milestone. Whether you need a streamlined efficacy screen or a comprehensive orthotopic metastasis study with longitudinal biomarker tracking, Alfa Cytology has the expertise and infrastructure to execute with excellence.

For research use only. Not intended for any clinical use.